LAM-002A
PreclinicalSmall molecule
LAM-002A is one of 11 small molecule programs targeting Frontotemporal Dementia. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Frontotemporal Dementia
#DrugCompanyPhaseTrials
1Celexa
AbbVieApproved
Namenda
AbbVieApproved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Rayos
RRoxane Laboratories
Approved
Glucophage
EMD SeronoApproved
Brintellix
TakedaPhase 2
Medrol
PfizerPhase 1
NS101
NNeuracle Science Co., LTD.
Phase 2
Lumbar Puncture
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Amyotrophic Lateral Sclerosis1 trial
Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LAM-002A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- OOrphAI Therapeutics